Job Description
Dendreon is making the battle against cancer personal. Founded on the belief that the immune system holds the key to the future of cancer care, Dendreon is committed to the delivery of treatments that harness the power of the body’s immune system to attack cancer cells.
If you are looking to positively impact the lives of patients, we want you to join our team.
Vision – Pioneering the future of immunotherapy.
Mission – Making the battle against cancer personal through immunotherapy treatments that extend lives.
The Dendreon Way. We are a purpose-driven, value-based culture. At Dendreon, we…..
- Put Patients First. Every day is a new opportunity to improve the lives of patients living with cancer.
- Act with Integrity. Be honest, transparent, and committed to doing what’s right in every situation.
- Build Trust. Building trust takes time. Engage teammates, be candid and transparent. Over communicate and seek feedback.
- Raise the Bar. Harness continuous improvement, foster innovation, and elevate our people.
- Drive Results. Be accountable and execute – we win together when everyone performs.
Dendreon is an Equal Employment Opportunity F/M/Disability/Vet/Sexual Orientation/Gender Identity / Affirmative Action employer and provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment, Dendreon is fighting for patients by making the battle against cancer personal. By harnessing the power of the body’s immune system, we help extend the lives of patients battling cancer.
Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 30,000 men with advanced prostate cancer have been prescribed PROVENGE. Today, we continue to push our research forward so that we may help even more patients fight cancer with personalized immunotherapy.
